The expression of the 70-kD 0 subunit of the interleukin 2 receptor (IL2R) has been examined on peripheral blood lymphocytes (PBL) obtained from patients receiving systemic infusions of 11,2. Using monoclonal antibodies directed against p70, flow cytometric analyses revealed a greater than threefold increase in expression of the IIr2R 0 chain on CD56+ natural killer (NK) cells from post-IL2 therapy PBL relative to pre-therapy cells . The level of p70 expression on the post- or nonspecific mitogenic stimuli, however, results in increased IL-2 and Tac synthesis, followed by a rapid increase in high affinity IL2R expression (1, 24) . This activation also leads to increased release of soluble Tac protein from the cells (25). Similar results were noted when purified T cells were cultured directly in IL2 (1, 19, 24, 26) . The latter observation suggests that IL2, when present in sufficient concentrations, directly activates resting Tac -cells through the intermediate affinity p70 0 chain, leading to the synthesis of IL2 and Tac and the formation of Tac/p70 IL-2R complexes . Subsequent autocrine responses to IL-2 would then be mediated by the newly formed high affinity receptors. Consistent with these in vitro observations, increased levels of soluble Tac have been observed in the sera of patients receiving systemic infusions of high-dose 11,2 (27, 28), in the sera of patients experiencing graft rejections (29), and in other forms of in vivo immune activation (30) .
or nonspecific mitogenic stimuli, however, results in increased IL-2 and Tac synthesis, followed by a rapid increase in high affinity IL2R expression (1, 24) . This activation also leads to increased release of soluble Tac protein from the cells (25) . Similar results were noted when purified T cells were cultured directly in IL2 (1, 19, 24, 26) . The latter observation suggests that IL2, when present in sufficient concentrations, directly activates resting Tac -cells through the intermediate affinity p70 0 chain, leading to the synthesis of IL2 and Tac and the formation of Tac/p70 IL-2R complexes . Subsequent autocrine responses to IL-2 would then be mediated by the newly formed high affinity receptors. Consistent with these in vitro observations, increased levels of soluble Tac have been observed in the sera of patients receiving systemic infusions of high-dose 11,2 (27, 28) , in the sera of patients experiencing graft rejections (29) , and in other forms of in vivo immune activation (30) .
Resting NK cells also appear phenotypically Tac -, suggesting that IL-2 activation of these cells may occur exclusively through the p70 a chain of the IIr2R (22, (31) (32) (33) .
Recent studies have further demonstrated that the majority of the resting NK cells are CD16' CD56dim and bind IL-2 through p70. However, a small subset of resting NK cells is distinguishable phenotypically as CD566"ghtCD16 -, and these cells bear high affinity IL2Rs (34, 35) . Whether expansion of one or both of these subsets resulted in the increased Tac expression observed after exposure ofresting NK cell populations to IL-2 in vitro (11, [20] [21] [22] is not known.
The functional role of these distinct NK cell subsets is also unclear, although it has been suggested that the CD16 -CD566°ghc subset bearing the high affinity IL2R may represent a precursor population capable of expanding and differentiating in response to low physiologic concentrations of 11,2 that occur naturally in vivo (34, 35) . This hypothesis is also attractive with regard to the in vivo immune activation observed in patients who have achieved steady-state serum IL2 levels of -30 U/ml during continuous infusions of 11,2 for the treatment of cancer (36) .
The exposure of heterogeneous populations of lymphocytes to high concentrations of IIr2 activates a non-MHCrestricted cytolytic activity due to the expansion of a population of large granular lymphocytes with properties of activated NK cells (36) (37) (38) . The cells mediating this lymphokine activated killer activity effectively lyse fresh tumor targets as well as various NK-resistant cultured tumor cell lines (38) . This observation, together with the demonstration of in vivo efficacy in murine tumor models, has led to testing ofIL2 as a therapeutic modality (36, 37, 39) . In clinical trials at a number of institutions, patients with renal cell carcinoma and melanoma have shown objective regression of tumor in response to a variety of IL-2 treatment regimens (39) (40) (41) (42) (43) .
In an effort to better characterize and modify further the in vivo effects of systemically administered IL-2, we have examined changes in lymphocyte function and phenotype after IL-2 therapy. Enhanced proliferative and cytotoxic activity in response to 11,2 treatment in vitro was observed with PBL obtained after IL-2 therapy (44) (45) (46) . These responses were mediated primarily by the CD56' NK cell subpopulation, a subset of the circulating lymphocytes that is significantly expanded in number during the course ofin vivo 11,2 therapy (45) (46) (47) (48) was added at 1 hg/mlfor30 min, cells were washed and resuspended, and analyzed immediately. For two-color fluorescence, cells were first stained as described above with appropriate dilutions of ascites fluid containing either TU27, Mik (31, or Mik 03 . After GAM-FITC staining, the cells were incubated for 10 min on ice in HBSS, 1% FCS, and 0.2% NaN3 containing 10,ug/ml purified control mouse IgG1 (MOPC 21; Sigma Chemical Co.) to block any free antibody binding sites on the bound GAM-FITC molecules. After blocking, cells were stained with either anti-CD3-PE or anti-CD56-PE for 30 min on ice, washed, and analyzed by flow cytometry. Control staining of TU27/GAM-FITC-stained cells with a PEconjugated isotype control antibody showed no nonspecific staining due to recognition of the PE-conjugated antibodies by bound GAM-FITC molecules (unpublished observations) . All samples were analyzed on a FACScan flow cytometer (Becton Dickinson & Co.) using FACScan Research and Consort 30 Software. All samples were gated on forward and side scatter. Propidium iodide was added at 1 tag/ml before analysis to allow exclusion of dead cells.
Median log fluorescence intensity (MFI) calculations were performed by subtracting the MFI of appropriate isotype control antibodies from the MFI of the positively stained samples. Thus, all MFI values presented represent relative increases in log fluorescence intensity over a background value assigned 0, allowing comparisons to be made between individual populations .
FACS. Freshly obtained, Ficoll-Hypaque-separated PBL were resuspended in HBSS containing 100 U/ml penicillinAtreptomycin, and 0.3% BSA. 1.8 x 108 cells were resuspended at 2.0 x 10'/ml and stained with anti-CD56-PE and anti-CD5-FITC. After rotating for 60 min at 4°C, the cells were washed twice and resuspended at a final concentration of 5 x 106/ml. Before cell sorting cells were passed through a Nytex membrane to achieve a single cell suspension . Sorting was performed on a FACStarPl°' flow cytometer (Becton Dickinson & Co.) . Purity of the CD56*-and CD5*-sorted populations was >99% upon restaining and reanalysis.
For purification of larger numbers of CD56* cells (>5.0 x 10'), negative depletions were performed using the anti-CD3 mAb OKT3 (Ortho Pharmaceuticals, Raritan, NJ) and immunomagnetic beads coupled to GAM IgG (Dynal Beads; Dynal, Inc., Great Neck, NY). Bead depletions were performed as described previously (44) . Reanalysis of CD3-depleted cells with anti-CD5 and anti-CD56 revealed purity of >95% .
Fc Receptor Blocking. Rabbit Ig (Sigma Chemical Co .) was resuspended at 20 mg/ml in HBSS and heat aggregated for 30 min at 65°C as described (54) . Patient PBL (5 x 106) were incubated in 200 F.1 HBSS containing 10 mg/ml aggregated rabbit Ig for 2 h at 4°C. Lower concentrations of rabbit IgG were not effective at blocking staining by anti-FcR mAbs (anti-CD16[Leu-11] directed against FcyRIII present on NK cells; S. Voss, unpublished observations) . Aliquots of cells were then removed and stained with either TU27, anti-CD16, anti-CD3, anti-CD56, or isotype control mAbs . FACS analyses were performed as described above. Neither monomeric rabbit or human Ig, nor aggregated human Ig, were found to be as effective as aggregated rabbit Ig in interacting with the FcRs expressed on NK cells (S . Voss, unpublished observations). Incubation of the patient's cells with rabbit Ig also had no effect on staining with anti-CD3 or anti-CD56.
FACS Analysis With Biotinylated H,2-lys. IIr2-lys-biotin was generously provided by Dr. Paul Simon, Glenolden Laboratory E.I . DuPont de Nemours & Co. (Glenolden, PA) and has been described previously (55) . Cells (106) were resuspended in 75 P.1 HBSS, 1% FCS, 0.1% NaN3 . 1 Ftg of either 11,2-lys-biotin or unbiotinylated control II,2 was added and the cells were incubated at 37°C for 10 min, followed by incubation on ice for an additional 60-90 min.
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After washing, cells were stained with PE-conjugated Streptavidin (Becton Dickinson Monoclonal Center) and either IgGl-FITC or anti-CD3-FITC to allow gating on the CD3-CD56* NK cell subpopulation . FACS analysis was performed as described above. '1s 1IL2 Binding Assay. IL2 binding assays were performed as described previously (6). 1211-IL2 was obtained from New England Nuclear (Boston, MA) and had a specific activity of 0.94-3.6 x 106 cpm/pmol . 50 P1 of cells were combined with 50,ul of respective serial dilutions of 121 1-11,2 in binding buffer (RPMI 1640, 10 mM Hepes, pH 7.2, 5 mg/ml BSA) . Patients' cells were at concentrations ranging from 2.5 to 8.8 x 10'/ml, such that final concentrations in the assay ranged from 1.25 to 4.4 x 106/data point. YT cells were at 8 x 106/ml. For experiments in which mAb GL439 was present, patient cells and YT cells were pretreated for 20 min on ice with GL439 at a final concentration of 50 lAg/ml . For experiments in which the mAb TU27 was also present, a 1:100 dilution of ascites fluid containing the antibody was included in the pretreatment of the cells. The cells and 1181-IIr2 were combined for 12 min at 37°C and then spun through a 200-iAl layer of silicone/paraffin oil (81:19) . Cold competition values were determined by including 2 Wg of unlabeled IL-2 (1 .3 1AM final concentration) in one assay tube with each cell sample and ranged from 0.2 to 0.4% of free counts . These binding assay conditions are sufficient to allow ->80% of the maximal binding observed after incubation for 40 min to occur (unpublished observations), and are consistent with published data demonstrating a t~h of association to intermediate affinity IIr2Rs of -4 .5 min (16) . Binding data were analyzed according to the method of Scatchard (56) .
Cell Surface Radioiodination and Immunoprecipitation. Before iodination cells were passed over Ficoll/Hypaque to insure good cell viability, 10' cells were labeled with 1.0 mCi 'III (New England Nuclear) using the glucose oxidase/lactoperoxidase method (EnzymobeadsR), essentially according to manufacturer's (Bio-Rad Laboratories, Richmond, CA) instructions. Briefly, cells were resuspended in a final volume of 125 F,1 of PBS, followed by addition of 50 P.1 Enzymobeads, 25 ul 1% (3-D glucose, and 1.0 mCi 1151, After 20-25 min at room temperature, cells were pelleted, washed four times with PBS, and solubilized in lysis buffer (20 mM Tris, pH 7.5, 140 mM NaCl, 0.1% deoxycholate, and 1% NP-40) containing 1 mM PMSF and 2.5 Fcg/ml each aprotinin, leupeptin, and antipain . Nuclei and debris were removed by centrifugation for 30 min at 100,000 g. Lysates were precleared twice by incubation with 25 14 (packed) mouse IgG agarose (Sigma Chemical Co .), followed by two additional preclearings with 25 pl (packed) Gammabind-protein G agarose (Genex, Gaithersburg, MD). Immunoprecipitations were performed by incubating aliquots of precleared lysates with 2-5 ul of ascites fluid containing either control IgG2a (UPC10) or anti-p70 (Mik /31) mAb. After 2-4 h on ice, 501AI Gammabind protein G agarose (1 :1 in PBS, pH 7.4,0 .05% thimerosal) was added. After 1-2 h at 4°C, precipitates were pelleted, washed four times with lysis buffer, two times with 10 mM Tris, pH 7.5, and resuspended in SDS-PAGE sample buffer. Afterboiling for 10 min, samples were analyzed on 9% SDS polyacrylamide gels under reducing conditions, as described (57) .
Results
Flow Cytometric Analysis of IL2R p55 and p70 Expression . Pre-and post-IL-2 therapy PBL were examined for expression of both the a (Tac) and a (p70) subunits of the IL 2R .
Consistent with our previous observations (44) , circulating PBL show a slight increase in Tac expression after in vivo A B C Pt . 25 Pre IL-2 Therapy Pt . 25 Post IL-2 Therapy Pt. 24 Post IL-2 Therapy
Figure 1 . Flow cytometric analysis of IL2R expression on pre-and post-11,2 therapy PBL. Cryopreserved PBL from patient 25 obtained before (A) or 24 h after (B) 11,2 therapy and from patient 24 after IL2 therapy (C) were thawed and stained with the indicated antibodies: anti-CD25-FITC, anti-CD3-PE, anti-CD56-PE, or the anti-p70 mAb TU27 . Staining with TU27 was followed by indirect fluorescent staining with GAM-FITC . Twocolor fluorescence was performed as described in Materials and Methods. Quadrant settings, distinguishing positive from background fluorescence, were determined for each marker based on staining with isotype control antibodies (not shown) . The results shown for patients 24 (C) and 25 (A and B) are representative of comparable data obtained from nine different patients (Table 1) . 1172 therapy; all Tac+ cells were CD3+CD56 -T cells (Fig. 1,  A and B) . No Tac expression was detected on the CD56' CD3 -NK cell population . Using TU27, a mAb directed against the p70 /3 chain of the IL2R, we and others have observed low but detectable levels of p70 on fresh NK cells obtained from healthy control donors (33) (34) (35) 58 , and S. Voss, unpublished observations) . Similar results were obtained when PBL from cancer patients were analyzed before in vivo IL2 therapy (Fig. 1 A) . These data indicate that the pattern of TU27 staining observed on PBL obtained from patients before initiating IL-2 therapy is similar to that observed with PBL from normal healthy donors. In contrast, when post-therapy PBL were examined, a dramatic increase in p70 expression was observed ( Fig. 1 B and  C) . This increase was limited to the CD56+ NK cell subset . Similar results were obtained with PBL from seven other patients receiving continuous infusions of IL2 (Table 1) . In all of the post-therapy PBL samples studied, bright TU27 staining of the CD56+ population was observed (Table 1) . Identical results were obtained using indirect fluorescent staining with the TU27 mAb (Fig. 1) or with TU27 directly conjugated to FITC (not shown) . Although some weak staining of CD3+ T cells with TU27 was occasionally observed (Fig.  1 B) , this observation has not been seen reproducibly with PBL from other patients (Fig. 1 C, Table I ) .
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Voss et al. For each sample, the number of events analyzed was similar (7,000-9,000), with the exception of pre-therapy cells gated on the CD56p opulation (1,500-1,700 events) . This difference is reflected in the difference in vertical scale between the pre-and post-therapy samples (B) .
The percentage of CD56+ cells in the pre-therapy PBL was usually <20% (not shown), while 42-88% of the posttherapy PBL from these patients were CD56+ (Table 1) . To compare the level of TU27 staining of the CD56+ :ells from pre-and post-therapy samples, we double stained cells with anti-CD56 and TU27 and directly compared TU27 fluorescence intensity on the CD56+-gated populations. Because the level of p70 expression detected by FACS on the post-therapy PBL samples is considerably higher than the levels reported by others on various cell populations (33-35, 49, 52, 58) , it was important to confirm our observations with TU27 using another anti-p70 mAb. We therefore repeated our flow cytometric analyses using Mik 01, an antip70 mAb that was derived independently from TU27 using a different cell line (YT rather than TIrMor) as an immunogen (52) . As presented in Fig . 3 , staining with Mik (31 resulted in the same increase in fluorescence intensity on the posttherapy PBL as that previously observed with TU27. This increase was again restricted to the CD56+ NK cell subpopulation . Furthermore, the level of expression of p70 on the patient's cells was again higher than that observed on YT. These experiments have been repeated with PBL from three patients with identical results and confirm our observations with TU27. Further confirmation was also obtained with Mik (33, another anti-p70 mAb that, in contrast to TU27 and Mik (31, does not compete with IL-2 for binding to p70 (49, 52) . The results of staining with Mik (33 are presented below as a component of the IL-2 binding analysis with biotinylated IIr2 (shown in Fig. 9 ). Effect ofFc Receptor Blocking on TU27 Staining ofPost-Therapy PBL. We and others have reported increased numbers of NK cells bearing Fcks ft-ykIIl, CD16) in post-IL2 therapy PBL (47, 59) . Even though the FcyRIII expressed on NK cells binds monomeric IgG poorly and monomeric murine IgG at undetectably low levels (60, 61) , it remained possible that the apparent increase in p70 expression observed on the post-therapy CD56+ NK cells was due to interaction of the anti-p70 mAbs with the FcRs present on these cells .
To rule out this trivial explanation for the increase in TU27 staining observed, post-therapy PBL were pre-incubated with heat-aggregated rabbit IgG to saturate all FcRs before staining with TU27. This FcR saturation treatment virtually eliminated the ability of these cells to be recognized by the anti-CD16 mAb, but had no effect on TU27 staining (Fig. 4) . These results, together with the negligible staining observed with appropriate isotype control mAbs, and the observation that both CD16+ and CD16 -post-therapy CD56+ NK cell subpopulations stain with TU27 with equal intensity (not shown), argue that the increased staining with the anti-p70 mAbs reflects an increase in p70 (3 chain expression, and not interaction of the anti-p70 mAbs with FeRs.
Proliferative Response of Post-Therapy CD56+ PBL to Ifr2. To evaluate the functional role of the p70 /3 chains expressed on the CD56+ post-therapy PBL in the response of these cells to 11,2, freshly obtained post-therapy PBL were sorted to 99% purity by FRCS using anti-CD56 and anti-CD5 mAbs. The CD56+CD5-cells were cultured for 48 h in increasing concentrations of IL-2 in the presence of the anti-p70 mAb TU27, the anti-p55 mAb GL439, or both . Representative results from experiments performed on three separate occasions are presented in Fig . 5 . TU27 completely inhibited the proliferative response of the cells to 11,2, while GL439 had no effect . In control experiments, GL439 produced a substantial inhibition of the proliferative response of fresh normal PBL to IL-2 (40-75% inhibition at IL-2 concentrations <0. The observation that GL439 (a mAb that inhibits IL-2 binding to the p55 Tic chain [51] ) had no effect on the 11,2-induced proliferative response of the post-therapy CD56+ NK cells (Fig . 5) suggested that high affinity IL2Rs were not contributing functionally in the proliferative response of the cells to IL2. To determine whether any high affinity binding sites, reflecting Tac involvement, could be detected on post-therapy NK cells, 125 1-IL2 binding assays were performed on post-therapy CD56+ NK cells (purified by immunomagnetic beads) in the presence and absence of the anti-p55 mAb GL439 (Fig. 6) . GL439 inhibited the high affinity component of the 125 1-IL2 binding to YT cells, a result consistent with previous studies demonstrating low level expression of Tac on YT cells, predominantly in the form of high affinity IL2R complexes (12, 13, 17) . In contrast, GL439 had no effect on 125 1-IL2 binding to the patient's cells. The absence of detectable high affinity binding sites confirms that the post-therapy NK cells do not utilize Tac/p70 high affinity receptor complexes for IL-2 binding. Under these experimental conditions, the 125 1-11,2 binding to YT cells demonstrates that even a very low level of high affinity binding on the patient's NK cells could have been detected .
Further 125 1-IL2 binding analyses were performed on post-therapy PBL from six additional patients in order to determine whether the increase in TU27 staining on the CD56+ cells was accompanied by a corresponding increase in IL2 binding sites . To reduce the contribution of the small 110 7 Voss et al . proportion of T cells (<20%) in these samples, the experiments were performed in the presence of GL439 . Since posttherapy CD56+ cells express no detectable Tic (Fig. 1) , their proliferation in response to 1172 is negligibly affected by GL439 (Fig. 5) , and no effect of GL439 on 125 1-IL2 binding could be demonstrated (Fig. 6) , we reasoned that the antibody would not alter the number or affinity of IL-2 binding sites on the CD56+ subpopulation . In the samples on which subsequent 125 1-IL2 binding assays were performed, CD56+ cells comprised an average of 85% of the total cell population (Table  1) . Representative Scatchard plots of 125 1-IL2 binding obtained from two patient samples and from control YT cells are shown in Fig . 7 . The patient sample curves were slightly curvilinear, reflecting either minor heterogeneity in receptor site affinities or experimental variability due to the very low level of bound radioisotope. Based on the results shown in Figs . 5 and 6, analysis of these data and that of the four additional patients studied was limited to best fit lines representing a single class of IL-2 binding sites ( Table 1) .
Comparison of 125 1-IL2 binding data for the patient samples and the control YT cells revealed that the patient cells expressed intermediate affinity receptors with roughly the same Kd as that of the receptors on the YT cells (Table 1) . Despite the high level of TU27 staining on the post-therapy cells in reference to the control YT cells, suggesting more p70 molecules on post-therapy PBL than on YT, only very low numbers of intermediate affinity 11,2 binding sites were detected on the post-therapy PBL (Table 1) . In fact, the number of binding sites was in the range previously observed by others for unstimulated NK cells (22, 58) , although lower than that determined by one group of investigators (34) . This 125 1-IL2 (Fig . 7) . These findings indicate a higher level of p70 expression on the post-therapy NK cells than on YT cells, as determined flow cytometrically using anti-p70 mAbs. These results also demonstrate that only a fraction of the p70 molecules expressed so abundantly on the surface of the post-therapy cells could form functional intermediate affinity II,2Rs comparable with those on YT cells . One explanation for this result, it could be argued, is that under the experimental conditions used in these studies (i.e., incubation for 12 min at 37°C), equilibrium binding has not occurred, making estimates of receptor number inaccurate. This is not likely to influence our interpretation of the results presented in Table 1 , however, which compare the level of IL-2 binding seen on patients' cells with that seen on YT cells handled in parallel under identical conditions . Furthermore, in our experience, >80-85% of the maximal binding (B..) observed after longer incubation periods had occurred by 12 min, consistent with a t~,, of association of -4.5 min to intermediate affinity IL2Rs (16) . This slight difference in B.,. observed after longer periods of incubation is unlikely to be the explanation for the 10-15-fold differences in the level of intermediate affinity and Dynal beads coupled to GAM IgG, as described (44) . Upon reanalysis after depletion, the Pt . 25 PBL were >95% pure for CD56+ NK cells . Pt . 25 PBL and YT cells were incubated with increasing concentrations of 1251-IL2 for 12 min at 37°C, followed by centrifugation through silicone/paraffin oil . Before addition of 1251-IL2, cells were preincubated for 30 min on ice with 50 jug/ml GL439 (O) or no antibody ( " ) .
incubations were carried out at 37°C for 25 min, a similar low level of IL2 binding to the patient's NK cells relative to YT was observed . It is thus apparent that the majority of the molecules on the surface of the patients' NK cells recognized by the anti-p70 mAbs were incapable of the level of intermediate affinity IL2 binding that would have been expected under the experimental conditions used, based on comparison with the level of anti-p70 mAb staining seen on the YT cells.
Competitive Inhibition of TU27 mAb Binding by 11,2. Since the flow cytometric data were collected on individual viable cells and the 11,2 binding assays were performed with large numbers of cells in bulk populations, it is difficult to make direct quantitative comparisons between the apparently discordant results of these two assays. TU27 and Mik 01 binding to post-therapy PBL was greater than that to YT cells by FACS analysis, whereas the 125 1-IL-2 binding to the patient PBL was considerably less than the binding to YT cells. We therefore felt it was important to evaluate IL2 binding on the post-therapy PBL relative to YT cells using flow cytometry. Since 11,2 and the TU27 mAb compete with one an-1109 Voss et al . Figure 7 . Scatchard analysis of representative 1 2 51-IL2 binding data . YT cells (A) or freshly thawed cryopreserved patients' cells (B and C) were incubated with increasing concentrations of 1251-IL2 for 12 min at 37°C, followed by centrifugation through silicone/paraffin oil . Before addition of 12SI-IL2, cells were preincubated for 20 min on ice with 50 pg/ml GL439 (O) or 50 p,g/ml GL439 + 1:100 dilution of ascites fluid containing TU27 ( " ) . In control experiments, preincubation of MT-1 cells, a Tac+ p70 -T cell line, with 50 ug/ml GL439 eliminated all specific 1251-11,2 binding to the low affinity Tac IIL2R subunit . Preincubation of MT-1 cells with ascites fluid containing TU27 had no effect on the 1251-IL2 binding (not shown) . Pt . 5
Pt . 25
IL-2-Biotin Mikg3 Figure 9 . FACS analysis of IL2 binding using biotinylated IL2-lys. To examine the distribution of IL-2 binding sites on the post-11,2 therapy patient PBL, PBL from Pts . 5 and 25, as well as YT cells, were incubated with 1 ug of either biotinylated 11,2-lys or control unbiotinylated IL2, followed by staining with PE-conjugated Streptavidin . Pt . 5 and Pt . 25 PBL were also stained with anti-CD3-FITC to allow electronic gates to be set on the CD3 -NK cell subpopulation . All cell populations were gated on forward and side scatter before analysis. Indirect staining of the same cell samples with Mik /33 and GAM-FITC is shown for comparison. For Mik 03 staining, the patients' PBL were not gated on the CD56+ NK cell subpopulation . Control staining with either unbiotinylated I1r2 or IgG1 isotype control mAb is represented in the histograms shown by dotted lines. Staining with either biotinylated IL2-lys or Mik 03 is represented by solid lines.
creased by 65% (Fig. 8) . Alternatively, if the majority of the p70 a chains recognized by TU27 on post-therapy PBL do not have intermediate affinity IL2 binding properties, then preincubation with excess 11,2 should minimally inhibit TU27 binding. In fact, when post-therapy cells were stained under identical conditions as the control YT cells, a decrease in MFI of only 16% could be demonstrated (Fig. 8) . (Fig . 9 ), indicating that the low level of IL-2 binding detected in the bulk population in 125 1-IL-2 binding assays is distributed uniformly throughout the CD56+ NK cell population . As a control, staining with the anti-p70 mAb Mik /33 was included (Fig. 9) , confirming our earlier observations with TU27 and Mik 01, and demonstrating that despite low levels of IL2-lys-biotin binding relative to YT cells, high levels of p70 (relative to YT) were expressed on the patients' NK cells .
Immunoprecipitation of p70 From Post-Therapy PBL and YT The data presented thus far indicate a discrepancy between the number of intermediate affinity IL-2 binding sites present on post-IL-2 therapy NK cells (measured by IL-2 binding) and the level of the p70 IL2R6 expressed on the cell surface, as detected by FACS analysis with anti-p70 mAbs. At least one of the mAbs used in the FACS analyses (Mik (33) clearly recognizes an epitope on p70 distinct from the epitope(s) recognized by Mik ail and TU27, since Mik /33, unlike Mik 01 and TU27, does not compete with IL2 for binding to p70. While it seems, therefore, unlikely that this panel of anti-p70 mAbs is recognizing some molecule other than p70 on the post-therapy PBL, immunoprecipitation experiments were undertaken to prove recognition of p70. As shown in These studies have evaluated the influence of in vivo IL2 administration on cell surface IL-2R expression . We and others have previously documented an increase in both the absolute number and the mean percentage of Tac+ PBL after IL2 therapy (28, 36, 45, 46) . Nevertheless, subsequent analyses showed that the majority of the post-therapy CD56' NK cells did not express detectable levels of Tac and maintained this minimal Tac expression upon further in vitro culture with IL-2 (44) . Furthermore, very low levels of soluble Tac were released during in vitro stimulation, relative to pre-therapy PBL, again suggesting a minimal role for Tac in the response of in vivo activated NK cells to IL-2 (44) .
In the studies reported here, we have examined patients' pre-and post-therapy PBL for the possibility of increased expression of the p70 /3 chain of the IL2R . When pre-and post-therapy cells from the same patient were stained with either antiTac or the anti-p70 mAb TU27, we again observed virtually no Tac+ CD56' cells ; the majority of the Tac expression was restricted to CD3+ T cells . In contrast, nearly all of the CD56+ cells stained brightly with TU27, while only dim staining of CD3+ cells was seen. When electronic gates were set on the CD56+CD3 -population, a comparison of the TU27 staining on pre-vs . post-therapy cells revealed an increase in TU27 fluorescence intensity on the posttherapy population, suggesting increased expression of the p70 0 chain on CD56+ NK cells induced by in vivo IL2.
FcR blocking experiments, as well as immunoprecipitation Figure 10 . SDS-PAGE analysis of radioiodinated cell surface proteins immunoprecipitated from YT and patient cell lysates. Pt 16 post-therapy PBL and YT cells were cell surface iodinated using the lactoperoxidase/glucose oxidase method. After pre-clearing with mouse IgG agarose and Gammabind protein G agarose, cell lysates were immunoprecipitated with either control IgG2a mAb (UPC10) or the anti-p70 mAb, Mik ,81 . Precipitates were washed extensively, solubilized in SDS-PAGE sample buffer containing O-ME, and analyzed on a 9% polyacrylamide gel . After staining and fixing, the gel was dried and exposed to autoradiographic film for 37 d. Standard molecular weights (in kilodaltons) are indicated at the left . A similar result was obtained using TU27 as the immunoprecipitating mAb (not shown) . data, demonstrated that this increased TU27 fluorescence intensity was not due to interaction of the anti-p70 mAb with FcRs.
A In this report, we have also demonstrated the lack ofhigh affinity IL2R expression on the post-therapy CD56+ NK cells, confirming FACS data from our laboratory (44) , and from others (59) , showing the lack of cell surface staining by the antiTac mAb. In addition, these cells appear to respond to IL-2 exclusively through the p70 a chain and do not appear to synthesize Tac and express high affinity IL-2R after exposure to IL-2 in vitro, since proliferative responses to 1172 were completely inhibited by the anti-p70 mAb TU27 and were unaffected by the antiTac mAb GL439 . Nagler et al . (34) and Caligiuri et al . (35) have recently demonstrated the presence of functional high affinity IL 2Rs on a small subset of resting NK cells that bear the CD56b°gh , CD16 -phenotype. These authors hypothesized that the high affinity IL-2R-bearing CD56br ight population of NK cells may represent a progenitor population capable of responding to low doses of IL2 by expanding and maturing into FcR-bearing NK cells. In most cases, the majority of the NK cells expanded in vivo are CD56b°ght, 40-60% of which generally coexpress FcR, as detected by the anti-CD16 mAb. Our in vivo data are thus consistent with this hypothesis and suggest that exposure to continuous infusions of IL-2 (during which steady-state IL-2 levels of -30 U/ml are attained) may lead to the expansion of CD56b°ght NK cells by virtue of the circulating concentrations of IL2 being sufficient to saturate high affinity IL2R. If this is the case, our data would further suggest that chronic exposure to 11,2 in vivo, while possibly leading to the expansion ofan NK cell subset originally characterized by the presence of high affinity IL2Rs, leads to the loss of high affinity IL-2R expression on the NK cells that return to the peripheral circulation from the lymphoid organs after cessation of IL-2 therapy. This result is consistent with 111 1
the observation that the CD56b°eht NK cells purified from fresh peripheral blood that initially express high affinity I1T2Rs rapidly downmodulate cell surface Tac expression upon in vitro culture in IL-2 (J. Phillips and L. Lanier, personal communication) . Another possibility, also consistent with these data, would be the in vivo activation by IL-2 of a small NK subpopulation that neither expresses nor utilizes the Tac molecule, with subsequent in vivo expansion enabling this initially small subset of NK cells to be the predominant NK cell phenotype in the post-therapy PBL . The molecular mechanisms regulating the level of p70 expression on the patients' post-therapy NK cells remain unclear. Our data, demonstrating an elevation in p70 expression without a corresponding elevation in the level of intermediate affinity 11,2 binding, suggest that the presence of the p70 # chain alone may not be the sole determinant of intermediate affinity IL2 binding. While both previous binding and crosslinking studies indicated that p70 was the IL2 binding component of the intermediate affinity IL2R, it appears from our data that some other level of regulatory control may be required to allow the p70 # chain to bind IL2. One explanation for the apparent discrepancy between the anti-p70 mAb staining and 11,2 binding data might be expression of immature or structurally modified forms of p70 that remain antigenically similar but lack IL-2 binding capabilities. This seems less likely in view of the immunoprecipitation results showing the 70-75-kD 0 chain as the predominant species specifically precipitated by Mik /31 (as well as Mik03 and TU27) from whole cell lysates prepared from cell surface-iodinated posttherapy patient PBL . Alternatively, it is conceivable that a conformational change in the 0 chain could be introduced by association with a putative y subunit or that a putative y subunit might itself bind IL2 . Crosslinking studies with 'III-IL-2 have revealed numerous other bands in addition to the 55-kD a and 70-kD a chains (1, 63, 64), any one of which could function to regulate the binding of IL-2 to the p70 0 chain . In immunoprecipitation experiments using the antip70 mAb TU11, Sugamura and coworkers (65) have demonstrated the association of a 64-kD molecule, p64 (which they have termed MR y), with the p70 (3 chain of high affinity IL-2R. Whether p64 is also a component of intermediate affinity IIr2Rs remains to be determined . It is tempting to speculate that p64, which could only be detected when IL-2 was bound to its receptor during the immunoprecipitation, plays a role in regulating the binding of IL-2 to the p70 a chain .
A number of other recent reports have also addressed the possible involvement of additional IL-2R subunits in the formation of functional IL2Rs (1, 52, 63, 64, [66] [67] [68] [69] . Transfection experiments in which the cDNA encoding the p70 ,Q chain was introduced into nonlymphoid cells failed to demonstrate intermediate affinity IL-2 binding despite good cell surface expression of p70, while transfection of the p70 cDNA into Jurkat cells, which express neither p55 nor p70, or into MT-1 cells, which express the p55 a chain but little to no p70 0 chain, produced functional intermediate and high affinity receptors, respectively (67, 68, and B. Freimark and R. Robb, unpublished observations) . Robb and coworkers (69) have also recently characterized the kinetic binding properties of p55/p70 IIr2R complexes expressed on cDNA-transfected CHO cells. These receptors, while displaying equilibrium binding properties characteristic of true high affinity I1r2Rs, appear to be pseudo high affinity, in that bound ID2 has a very rapid rate of dissociation from these receptors (at least 10-fold greater than the rate of dissociation seen with HUT 102 cells) (69) . Based on these data, one can speculate that at least one function of additional Ilr2R subunits might be to stabilize the IIr2/0 chain complex and slow the rate of dissociation of IIr2 from p70. Whether this is the explanation for the discrepant low level of IL2 binding, despite the high level of p70 expression, observed on the post-II,2 therapy
